Tisolagiline
Small moleculeexperimental
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Jul 29, 2025 (NCT07009171)
Timeline
2020s
- Jan 1, 2025
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
- Monoamine oxidase BINHIBITOR
MAOB inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
C[C@H](NCc1ccc(-c2ccc(C(F)(F)F)cc2)cc1)C(N)=O- Mol. weight
- 322.33 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL5314546 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07027072 | Phase 2 | Aug 6, 2025 | NeuroBiogen Co., Ltd |
| NCT07009171 | Phase 2 | Jul 29, 2025 | NeuroBiogen Co., Ltd |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| NeuroBiogen Co., Ltd | For profit | 2 | 2 | 1 | 2025 |
1 organizations
Page 1 / 1